Trials / Conditions / Urinary Bladder, Neurogenic

Urinary Bladder, Neurogenic

29 registered clinical trials studyying Urinary Bladder, Neurogenic — 8 currently recruiting.

Status	Trial	Sponsor	Phase
Not Yet Recruiting	A Randomized, Placebo-controlled Trial of Nitrous Oxide During In-office Bladder Botox Injections NCT07387315	TriHealth Inc.	Phase 4
Recruiting	Effect of Urethral Balloon Dilatation on Urinary Retention After Spinal Cord Injury NCT06978205	Qilu Hospital of Shandong University	N/A
Recruiting	NXT Post-Market Clinical Follow-up NCT06336304	Laborie Medical Technologies Inc.	—
Recruiting	Feasibility of Triggered Sacral Neuromodulation for Neurogenic Bladder NCT05141487	VA Office of Research and Development	—
Recruiting	Heart Rate Variability and Anxiety During Urinary Bladder Catheterization NCT05380661	University of British Columbia	N/A
Completed	Cystometry Using a Novel Microsensor System in Patients With Neurogenic Bladder Dysfunction NCT06445426	Sunnaas Rehabilitation Hospital	—
Unknown	Multicenter Observational Study for the Evaluation in Clinical Practice of Urinary Disorders in Multiple Scler NCT05075642	ASP 7 Ragusa	—
Terminated	Botulinum Toxin A vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients With Multiple Scle NCT04819360	Brigitte Schürch	Phase 4
Completed	Ambulatory Closed-loop Stimulation for Bladder Control NCT05740527	MetroHealth Medical Center	N/A
Active Not Recruiting	Cystoealstometer (Bladder Monitor Device)-Home Use NCT05232253	University of Iowa	N/A
Recruiting	Recovery of Bladder and Sexual Function After Human Spinal Cord Injury NCT04193709	University of Louisville	N/A
Completed	Feasibility Study of Transcutaneous Tibial Nerve Stimulation for Urinary Symptoms in People With Multiple Scle NCT04528784	University of Limerick	N/A
Recruiting	Measurement of Bladder Pressure With a Novel External Device (Cystomanometer) - Home Use NCT04128709	Christopher Cooper	N/A
Unknown	Mirabegron and Oxybutynin Safety and Efficacy Trial in Spinal Cord Injury NCT03187795	Kessler Foundation	Phase 2
Enrolling By Invitation	Measurement of Bladder Pressure With a Novel External Device, Comparison to Urodynamics Testing NCT03456089	Christopher Cooper	N/A
Completed	Connected Catheter Clinical Feasibility Study( CFS) NCT03405285	Spinal Singularity	N/A
Unknown	Urinary Disorders in Patients With Multiple Sclerosis: Invasive Vs Non-invasive Investigations. NCT03336424	Saint-Joseph University	N/A
Unknown	A Prospective Evaluation of the Catheter Science C3 "Umbrella Catheter." NCT03353571	Dr. Gaines W. Hammond Jr. MD FACS	N/A
Active Not Recruiting	Pediatric Urology Recovery After Surgery Endeavor (PURSUE) NCT03245242	Washington University School of Medicine	—
Completed	Observational Study of Botulinum Toxin Type A in Patients With Urinary Incontinence Associated With Overactive NCT02673047	Allergan	—
Completed	Transcutaneous Peripheral Neuromodulation for Neurogenic Bladder NCT02582151	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	N/A
Completed	Reduction of Bladder Injection Pain With Belladonna Opiate Suppository NCT02600715	Edgar LeClaire, MD	Phase 4
Completed	Open-label Long-term Extension Study of Fesoterodine in Japanese Subjects With Neurogenic Detrusor Overactivit NCT02501928	Pfizer	Phase 3
Terminated	Urodynamic and Clinical Efficacy of Mirabegron for Neurogenic Bladder Patients NCT02044510	London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's	Phase 2 / Phase 3
Completed	Evaluation of a Bowel and Bladder Health Management Program for Individuals With Spinal Cord Injury (SCI) NCT01920243	University of Michigan	N/A
Completed	Detrusor Contraction During the Ice-water-test NCT01773213	Balgrist University Hospital	N/A
Completed	A Study To Find Out How Fesoterodine Works In Children Aged 6 To 17 Years With Bladder Overactivity Caused By NCT01557244	Pfizer	Phase 3
Completed	Pharmacokinetics and Safety Study With Alfuzosin in Children and Adolescents With Elevated Detrusor Leak Point NCT00629720	Sanofi	Phase 3
Completed	Efficacy and Tolerability of Propiverine Hydrochloride in Patients With Neurogenic Detrusor Overactivity NCT01530620	APOGEPHA Arzneimittel GmbH	Phase 3